Biotechnology
Laminar Pharma Announces first open-label Progression-Free Survival data for LAM561 in combination with standard of Care in First-Line Therapy for Newly Diagnosed Glioblastoma MGMT-methylated patients
PALMA DE MALLORCA, Spain, March 5, 2025 /PRNewswire/ -- Laminar Pharma, a leader in the development of innovative cancer therapy based on membrane lipid therapy, announced today optimistic results from its ongoing clinical trial evaluating LAM561 for the treatment of newly diagnosed glioblastoma ...
2025-03-05 22:45
1968
Ascend Advanced Therapies Appoints John Chiminski as Chair and Karen Flynn as Independent Director
ROCKVILLE, Md., March 5, 2025 /PRNewswire/ -- Ascend Advanced Therapies (Ascend)
2025-03-05 22:33
2553
Prenetics Announces Fourth Quarter and Full Year 2024 Financial Results, Provides 2025 Guidance
Revenue grew 93.5% to $10.5 million in the fourth quarter and 40.9% year-over-year to$30.6 million in 2024 Cash and short-term assets of $84.8 million as of December 31, 2024 Provides first quarter and full year 2025 guidance Projects full year 2025 revenue of $73 million to $85 million, driven ...
2025-03-05 21:32
4239
XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC
- XPOVIO® is the first and only approved XPO1 inhibitor in Indonesia. - From the second half of 2024 to now, XPOVIO® was successively approved in Thailand, Malaysia and Indonesia, significantly expanding Antengene's commercial presence in APAC. To date, XPOVIO® has been approved for multiple ind...
2025-03-05 13:00
2426
Callio Therapeutics Launches with US$187 Million Series A to Advance Multi-Payload Antibody-Drug Conjugate Platform Through Clinical Proof-of-Concept
* Frazier Life Sciences launches Callio Therapeutics based on multi-payload antibody-drug conjugate technology and programs exclusively in-licensed from Singapore-based Hummingbird Bioscience * Financing led by Frazier Life Sciences with significant participation from Jeito Capital alongside o...
2025-03-03 22:00
2877
Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics
* First ever head-to-head comparison of gut microbiome changes associated with ibezapolstat (IBZ) to other anti-CDI antibiotics in a germ-free mouse model * Changes in alpha and beta microbiome diversities following IBZ treatment were less pronounced compared to those observed in vancomycin (VA...
2025-03-03 21:00
1694
Head-to-Head Against Pembrolizumab: Innovent Announces First Patient Dosed in the First Pivotal Study of IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma
SAN FRANCISCO and SUZHOU, China, March 3, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metaboli...
2025-03-03 08:00
4472
A*STAR And MojiaBio To Develop Next-gen Sustainable Biomanufacturing Platform In Singapore
SINGAPORE, Feb. 28, 2025 /PRNewswire/ -- This initiative aims to produce
eco-friendly bio-based molecules from low-cost, eco-friendly sources. Key
benefits include:
2025-02-28 18:00
2715
Everest Medicines to Hold Investor Calls with Updates on mRNA Therapeutic Vaccine Programs
SHANGHAI, Feb. 28, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines, today announced that it will hold investor...
2025-02-28 14:28
4361
KBP to Contest Injunction Obtained by Novo Nordisk
SINGAPORE, Feb. 28, 2025 /PRNewswire/ -- KBP Biosciences Pte. Ltd. (the "Company ") today issued a statement addressing a recent decision by the Singapore International Commercial Court ("SICC"), which granted an injunction sought by Novo Nordisk A/S ("Novo Nordisk") against the Company and its fo...
2025-02-28 09:00
3237
EpiVax Strengthens Technology Leadership Amid Immunoinformatics Advancements
PROVIDENCE, R.I., Feb. 27, 2025 /PRNewswire/ -- EpiVax, Inc. proudly announces the appointment ofGuilhem Richard as Chief Technology Officer. Dr. Richard joined EpiVax's immunoinformatics team in 2014 and spearheaded the development of a new computational platform for developing personalized, neo...
2025-02-27 22:05
2617
Metabolon Unveils New Multiomics Biomarker Discovery Functionality via its Industry-leading Integrated Bioinformatics Platform
Metabolon's expertise extends beyond metabolomics to include data insights and software solutions for multiomics research MORRISVILLE, N.C., Feb. 27, 2025 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, dia...
2025-02-27 22:00
2203
WuXi Biologics Again Passed GMP Inspection by Japan PMDA
WUXI, China, Feb. 27, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has again passed the GMP inspection byJapan's Pharmaceuticals and Medical Devices Agency (PMDA) for it...
2025-02-27 16:30
3438
First Patient Dosed in a Phase III Clinical Study of Anti-HER2 Biparatopic ADC JSKN003 for the Treatment of HER2-positive Breast Cancer
SUZHOU, China, Feb. 27, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-301) of anti-HER2 bip...
2025-02-27 14:06
4167
The debate on MSCs is over; it's time to promote MSC therapy in practice
TIANJIN, China, Feb. 27, 2025 /PRNewswire/ -- The debate on MSCs, mesenchymal stromal cells versus mesenchymal stem cells, continued for more than two decades (since 2006), being the major obstacle for MSCs study and clinical application. The major issue focuses on mesenchymal stem cells could no...
2025-02-27 12:57
3404
ECR 2025: Esaote Group presents Integrated Medical Imaging Solutions and unveils innovations in Ultrasound Technology
Ebit showcases SUITESTENSA ZEfiRO: the new "cloud-native" PACS with diagnostic viewer VIENNA, Feb. 26, 2025 /PRNewswire/ -- Esaote Group, a leading Italian innovator in medical imaging - ultrasound, dedicated magnetic resonance and medical IT -presents its new portfolio of imaging solutions at t...
2025-02-26 21:00
2600
FDA Accepts BLA for TLX250-CDx (Zircaix®) for Kidney Cancer Imaging, Grants Priority Review
MELBOURNE, Australia, Feb. 26, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces thatthe United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for its breakthrough investigational k...
2025-02-26 08:49
2162
Everest Medicines Presents Complete Maintenance Period Data for Etrasimod at ECCO 2025
* Data confirms significant clinical and endoscopic benefits of etrasimod 2mg after 40 weeks of maintenance treatment * Etrasimod demonstrates robust efficacy across multiple endpoints, including mucosal healing, endoscopic normalization, and histological remission * Safety profile remains c...
2025-02-26 07:45
2264
LabConnect and Australian Clinical Labs' Specialised Trials Announce Strategic Partnership in Australia and Asia Pacific Region
PORT MELBOURNE, Australia and JOHNSON CITY, Tenn., Feb. 24, 2025 /PRNewswire/ -- LabConnect and Australian Clinical Labs' (ACL) Specialised Trials have forged a strategic partnership to expand support of clinical trials inAustralia and the Asia-Pacific region. This exclusive, multi-year agreement...
2025-02-24 22:06
2451
Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI
* Major finding provides mechanistic explanation for ibezapolstat's (IBZ) selectivity in that the predicted bactericidal interaction between IBZ and its target DNA pol IIIC is conserved across most of the Bacillota phylum, including C. difficile, while certain beneficial taxa are naturally resi...
2025-02-24 21:00
1973
Week's Top Stories
Most Reposted
Marina Bay precinct partners UOB, Marina Bay Sands and Singapore Tourism Board, together with Disney Cruise Line, to illuminate Singapore's skyline with a fireworks sky show
[Picked up by 328 media titles]
2026-02-19 14:30
Never Miss a Message: Agoda's Customer Support Now Travels With You
[Picked up by 326 media titles]
2026-02-24 12:00
NextFin Asia: A New Dedicated Fund for the Catapult: Inclusion SE Asia Program to Further Scale Inclusive Finance Fintechs in ASEAN
[Picked up by 311 media titles]
2026-02-23 08:00
Klook and Osaka Convention & Tourism Bureau sign MoU to advance inbound tourism and foster socio-economic development throughout Osaka Prefecture
[Picked up by 301 media titles]
2026-02-24 16:13
Vitafoods Asia 2026 Expands by 30%: A Bigger, More Dynamic Trade Event with Exciting New Features & Increased International Participation
[Picked up by 288 media titles]
2026-02-23 10:09